CLS Therapeutics LLC 13D and 13G filings for Xenetic Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-18 1:45 pm Purchase |
2024-03-18 | 13D | Xenetic Biosciences, Inc. XBIO |
CLS Therapeutics LLC | 215,964 14.000% |
17,076 (+8.59%) |
Filing |
| 2023-09-18 12:21 pm Purchase |
2023-09-05 | 13D | Xenetic Biosciences, Inc. XBIO |
CLS Therapeutics LLC | 198,888 13.000% |
51,388 (+34.84%) |
Filing |
| 2023-06-15 5:20 pm Sale |
2023-06-14 | 13D | Xenetic Biosciences, Inc. XBIO |
CLS Therapeutics LLC | 147,500 9.700% |
-0 (-0.00%) |
Filing |
| 2022-10-21 4:19 pm Purchase |
2022-10-12 | 13G | Xenetic Biosciences, Inc. XBIO |
CLS Therapeutics LLC | 147,500 9.700% |
147,500 (New Position) |
Filing |